No headlines found.
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
Globe Newswire (Fri, 10-Jan 8:23 AM ET)
Globe Newswire (Tue, 10-Dec 7:30 AM ET)
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
Lava Therapeutics N.V. - trades on the NASDAQ stock market under the symbol LVTX.
As of January 31, 2025, LVTX stock price was flat at $0.97 with 10,429 million shares trading.
LVTX has a beta of 1.47, meaning it tends to be more sensitive to market movements. LVTX has a correlation of 0.05 to the broad based SPY ETF.
LVTX has a market cap of $25.50 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, LVTX traded as high as $7.38 and as low as $.88.
LVTX has underperformed the market in the last year with a return of -43.9%, while the SPY ETF gained +24.4%. In the last 3 month period, LVTX fell short of the market, returning -49.5%, while SPY returned +4.4%. However, in the most recent 2 weeks LVTX has outperformed the stock market by returning +3.3%, while SPY returned +2.1%.
LVTX support price is $.93 and resistance is $1.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LVTX shares will trade within this expected range on the day.